Bio Contact News Today

PALO ALTO, Calif., June 03, 2024 -- BridgeBio Pharma, Inc. , a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that members of its management team, along...

G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib ...

- Pepper Bio will Gain Exclusive Rights for the Clinical Development, Regulatory Submissions, and Commercialization of Lerociclib in the US, Europe, Japan, and All Other Global Markets Excluding...

Boca Raton, Florida, April 23, 2024 --  INmune Bio, Inc.  , a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight...

PALO ALTO, Calif., April 10, 2024 -- BridgeBio Pharma, Inc. , a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on April 5, 2024, the...

Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast Cancer Boca Raton, Florida, April 08,...

- Submitted New Drug Application to US Food and Drug Administration for acoramidis for the treatment of transthyretin amyloid cardiomyopathy based on positive results of Phase 3 ATTRibute-CM trial,...

PALO ALTO, Calif., Feb. 06, 2024 -- BridgeBio Pharma, Inc. , a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on February 05, 2024, the...

Boca Raton, Florida, Feb. 06, 2024 --  INmune Bio, Inc.  , a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease with...

The Phase II clinical trial in patients with Alzheimer’s disease with neuroinflammation is on track to complete enrollment mid-2024 with top line data expected approximately six months after the...